UA125519C2 - Сполуки і композиції і їх застосування - Google Patents

Info

Publication number

UA125519C2

UA125519C2 UAA201901971A UAA201901971A UA125519C2 UA 125519 C2 UA125519 C2 UA 125519C2 UA A201901971 A UAA201901971 A UA A201901971A UA A201901971 A UAA201901971 A UA A201901971A UA 125519 C2 UA125519 C2 UA 125519C2

Authority

UA

Ukraine

Prior art keywords

disorder

pharmaceutically acceptable

methyl

acceptable salt

syndrome

Prior art date

2016-07-29

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 268
• 239000000203 mixture Substances 0.000 title claims description 181
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 141
• 208000035475 disorder Diseases 0.000 claims abstract description 100
• 208000020016 psychiatric disease Diseases 0.000 claims abstract description 57
• 208000012902 Nervous system disease Diseases 0.000 claims abstract description 56
• 238000000034 method Methods 0.000 claims abstract description 54
• 230000000926 neurological effect Effects 0.000 claims abstract description 46
• 208000025966 Neurological disease Diseases 0.000 claims abstract description 42
• 229910052739 hydrogen Inorganic materials 0.000 claims description 158
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 157
• 239000001257 hydrogen Substances 0.000 claims description 156
• 150000003839 salts Chemical class 0.000 claims description 131
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 130
• -1 (C1-Cv)halogenoxy Chemical group 0.000 claims description 104
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 98
• 238000006243 chemical reaction Methods 0.000 claims description 86
• 239000011737 fluorine Substances 0.000 claims description 62
• 229910052731 fluorine Inorganic materials 0.000 claims description 62
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 60
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 55
• 239000003814 drug Substances 0.000 claims description 54
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
• 208000011580 syndromic disease Diseases 0.000 claims description 51
• 208000028017 Psychotic disease Diseases 0.000 claims description 46
• 208000019901 Anxiety disease Diseases 0.000 claims description 44
• 208000024891 symptom Diseases 0.000 claims description 43
• 201000010099 disease Diseases 0.000 claims description 41
• 206010015037 epilepsy Diseases 0.000 claims description 40
• 208000002193 Pain Diseases 0.000 claims description 39
• 229940079593 drug Drugs 0.000 claims description 38
• 208000024827 Alzheimer disease Diseases 0.000 claims description 35
• 238000012360 testing method Methods 0.000 claims description 32
• 208000010877 cognitive disease Diseases 0.000 claims description 31
• 230000016571 aggressive behavior Effects 0.000 claims description 30
• 239000000460 chlorine Substances 0.000 claims description 30
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 29
• 229910052801 chlorine Inorganic materials 0.000 claims description 29
• 208000014094 Dystonic disease Diseases 0.000 claims description 28
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
• 238000011282 treatment Methods 0.000 claims description 28
• 208000020401 Depressive disease Diseases 0.000 claims description 27
• 206010001497 Agitation Diseases 0.000 claims description 26
• 238000013019 agitation Methods 0.000 claims description 26
• 230000000694 effects Effects 0.000 claims description 26
• 208000010118 dystonia Diseases 0.000 claims description 25
• 208000024714 major depressive disease Diseases 0.000 claims description 25
• 208000018737 Parkinson disease Diseases 0.000 claims description 24
• 201000000980 schizophrenia Diseases 0.000 claims description 24
• ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims description 23
• 208000020925 Bipolar disease Diseases 0.000 claims description 23
• 206010010904 Convulsion Diseases 0.000 claims description 23
• 229910052736 halogen Inorganic materials 0.000 claims description 23
• 150000002367 halogens Chemical class 0.000 claims description 23
• 239000000126 substance Substances 0.000 claims description 22
• 206010012289 Dementia Diseases 0.000 claims description 21
• 125000000217 alkyl group Chemical group 0.000 claims description 21
• 230000036506 anxiety Effects 0.000 claims description 21
• 208000016285 Movement disease Diseases 0.000 claims description 20
• 206010034010 Parkinsonism Diseases 0.000 claims description 20
• 208000028698 Cognitive impairment Diseases 0.000 claims description 19
• 125000003282 alkyl amino group Chemical group 0.000 claims description 19
• 230000006399 behavior Effects 0.000 claims description 19
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
• 206010044565 Tremor Diseases 0.000 claims description 18
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
• 150000002430 hydrocarbons Chemical class 0.000 claims description 16
• 241000699670 Mus sp. Species 0.000 claims description 15
• 229930195733 hydrocarbon Natural products 0.000 claims description 15
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
• 230000007958 sleep Effects 0.000 claims description 15
• 230000008448 thought Effects 0.000 claims description 15
• 239000004215 Carbon black (E152) Substances 0.000 claims description 14
• 208000027089 Parkinsonian disease Diseases 0.000 claims description 14
• 201000003631 narcolepsy Diseases 0.000 claims description 14
• 208000004296 neuralgia Diseases 0.000 claims description 14
• 208000019116 sleep disease Diseases 0.000 claims description 14
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 13
• 125000001931 aliphatic group Chemical group 0.000 claims description 13
• 208000030336 Bipolar and Related disease Diseases 0.000 claims description 12
• 208000012661 Dyskinesia Diseases 0.000 claims description 12
• 208000023105 Huntington disease Diseases 0.000 claims description 12
• 230000003542 behavioural effect Effects 0.000 claims description 12
• 201000006417 multiple sclerosis Diseases 0.000 claims description 12
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
• 208000011117 substance-related disease Diseases 0.000 claims description 12
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 11
• 230000001684 chronic effect Effects 0.000 claims description 11
• 239000002609 medium Substances 0.000 claims description 11
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 11
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 10
• 206010061334 Partial seizures Diseases 0.000 claims description 10
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 10
• 206010007776 catatonia Diseases 0.000 claims description 10
• 125000001188 haloalkyl group Chemical group 0.000 claims description 10
• 230000036651 mood Effects 0.000 claims description 10
• 208000019906 panic disease Diseases 0.000 claims description 10
• 206010003591 Ataxia Diseases 0.000 claims description 9
• 208000020706 Autistic disease Diseases 0.000 claims description 9
• 208000007514 Herpes zoster Diseases 0.000 claims description 9
• 208000019022 Mood disease Diseases 0.000 claims description 9
• 125000001153 fluoro group Chemical group F* 0.000 claims description 9
• 230000001771 impaired effect Effects 0.000 claims description 9
• 208000031091 Amnestic disease Diseases 0.000 claims description 8
• 208000008035 Back Pain Diseases 0.000 claims description 8
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 8
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 8
• 239000002253 acid Substances 0.000 claims description 8
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 8
• 201000007186 focal epilepsy Diseases 0.000 claims description 8
• 230000036541 health Effects 0.000 claims description 8
• 206010022437 insomnia Diseases 0.000 claims description 8
• HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 claims description 8
• 230000002085 persistent effect Effects 0.000 claims description 8
• 238000000926 separation method Methods 0.000 claims description 8
• 201000002859 sleep apnea Diseases 0.000 claims description 8
• 206010002942 Apathy Diseases 0.000 claims description 7
• 206010003805 Autism Diseases 0.000 claims description 7
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 7
• 208000027691 Conduct disease Diseases 0.000 claims description 7
• 206010019233 Headaches Diseases 0.000 claims description 7
• 208000019695 Migraine disease Diseases 0.000 claims description 7
• 208000002033 Myoclonus Diseases 0.000 claims description 7
• 208000037158 Partial Epilepsies Diseases 0.000 claims description 7
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 7
• 206010041349 Somnolence Diseases 0.000 claims description 7
• 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 7
• 206010043269 Tension headache Diseases 0.000 claims description 7
• 208000008548 Tension-Type Headache Diseases 0.000 claims description 7
• 125000002252 acyl group Chemical group 0.000 claims description 7
• 230000003920 cognitive function Effects 0.000 claims description 7
• 230000006735 deficit Effects 0.000 claims description 7
• 208000024732 dysthymic disease Diseases 0.000 claims description 7
• 231100000869 headache Toxicity 0.000 claims description 7
• 206010027599 migraine Diseases 0.000 claims description 7
• 208000021722 neuropathic pain Diseases 0.000 claims description 7
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 7
• 208000020685 sleep-wake disease Diseases 0.000 claims description 7
• ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical group C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 claims description 6
• 208000000044 Amnesia Diseases 0.000 claims description 6
• 208000006820 Arthralgia Diseases 0.000 claims description 6
• 206010008748 Chorea Diseases 0.000 claims description 6
• 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 6
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 6
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
• 208000004547 Hallucinations Diseases 0.000 claims description 6
• 208000005793 Restless legs syndrome Diseases 0.000 claims description 6
• 206010041250 Social phobia Diseases 0.000 claims description 6
• 206010044074 Torticollis Diseases 0.000 claims description 6
• 201000004810 Vascular dementia Diseases 0.000 claims description 6
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
• 208000029560 autism spectrum disease Diseases 0.000 claims description 6
• 208000012601 choreatic disease Diseases 0.000 claims description 6
• 235000014632 disordered eating Nutrition 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 230000004064 dysfunction Effects 0.000 claims description 6
• 208000002320 spinal muscular atrophy Diseases 0.000 claims description 6
• 208000037857 Alzheimer's disease agitation Diseases 0.000 claims description 5
• 208000001573 Cataplexy Diseases 0.000 claims description 5
• 208000001387 Causalgia Diseases 0.000 claims description 5
• 206010012218 Delirium Diseases 0.000 claims description 5
• 206010012335 Dependence Diseases 0.000 claims description 5
• 201000010374 Down Syndrome Diseases 0.000 claims description 5
• 208000028389 Nerve injury Diseases 0.000 claims description 5
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 5
• 208000008589 Obesity Diseases 0.000 claims description 5
• 208000024791 Schizotypal Personality disease Diseases 0.000 claims description 5
• 208000006011 Stroke Diseases 0.000 claims description 5
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 5
• 208000016620 Tourette disease Diseases 0.000 claims description 5
• 230000001154 acute effect Effects 0.000 claims description 5
• 239000002671 adjuvant Substances 0.000 claims description 5
• 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 5
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 5
• 230000036461 convulsion Effects 0.000 claims description 5
• 230000003247 decreasing effect Effects 0.000 claims description 5
• 238000011161 development Methods 0.000 claims description 5
• 230000008451 emotion Effects 0.000 claims description 5
• 201000003104 endogenous depression Diseases 0.000 claims description 5
• 201000006517 essential tremor Diseases 0.000 claims description 5
• 230000013016 learning Effects 0.000 claims description 5
• 230000015654 memory Effects 0.000 claims description 5
• 230000008764 nerve damage Effects 0.000 claims description 5
• 235000020824 obesity Nutrition 0.000 claims description 5
• 230000000750 progressive effect Effects 0.000 claims description 5
• 208000022610 schizoaffective disease Diseases 0.000 claims description 5
• 208000022925 sleep disturbance Diseases 0.000 claims description 5
• JDVFUAXVBAFSKH-UHFFFAOYSA-N 4,5-difluoro-1,3-dioxole Chemical compound FC1=C(F)OCO1 JDVFUAXVBAFSKH-UHFFFAOYSA-N 0.000 claims description 4
• 208000006888 Agnosia Diseases 0.000 claims description 4
• 206010001541 Akinesia Diseases 0.000 claims description 4
• 208000009575 Angelman syndrome Diseases 0.000 claims description 4
• 206010003062 Apraxia Diseases 0.000 claims description 4
• 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 4
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 4
• 208000006561 Cluster Headache Diseases 0.000 claims description 4
• 206010010071 Coma Diseases 0.000 claims description 4
• 206010012239 Delusion Diseases 0.000 claims description 4
• 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 4
• 206010013496 Disturbance in attention Diseases 0.000 claims description 4
• 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 4
• 206010013952 Dysphonia Diseases 0.000 claims description 4
• 206010013954 Dysphoria Diseases 0.000 claims description 4
• 208000030814 Eating disease Diseases 0.000 claims description 4
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
• 208000001640 Fibromyalgia Diseases 0.000 claims description 4
• 208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
• 206010065390 Inflammatory pain Diseases 0.000 claims description 4
• 208000027747 Kennedy disease Diseases 0.000 claims description 4
• 201000005802 Landau-Kleffner Syndrome Diseases 0.000 claims description 4
• 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
• 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 4
• 208000009571 Myoclonic Cerebellar Dyssynergia Diseases 0.000 claims description 4
• 208000001294 Nociceptive Pain Diseases 0.000 claims description 4
• 206010073211 Postural tremor Diseases 0.000 claims description 4
• 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
• 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims description 4
• 206010071141 Rasmussen encephalitis Diseases 0.000 claims description 4
• 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims description 4
• 208000030988 Schizoid Personality disease Diseases 0.000 claims description 4
• 208000008765 Sciatica Diseases 0.000 claims description 4
• 208000005439 Sleep paralysis Diseases 0.000 claims description 4
• 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 4
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 4
• 238000004458 analytical method Methods 0.000 claims description 4
• 208000024823 antisocial personality disease Diseases 0.000 claims description 4
• 206010005159 blepharospasm Diseases 0.000 claims description 4
• 230000000744 blepharospasm Effects 0.000 claims description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
• 230000002490 cerebral effect Effects 0.000 claims description 4
• 208000026725 cyclothymic disease Diseases 0.000 claims description 4
• 231100000868 delusion Toxicity 0.000 claims description 4
• 229960003638 dopamine Drugs 0.000 claims description 4
• 206010014599 encephalitis Diseases 0.000 claims description 4
• 208000028329 epileptic seizure Diseases 0.000 claims description 4
• 201000002904 focal dystonia Diseases 0.000 claims description 4
• 208000029364 generalized anxiety disease Diseases 0.000 claims description 4
• 208000016354 hearing loss disease Diseases 0.000 claims description 4
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
• 230000004770 neurodegeneration Effects 0.000 claims description 4
• 201000001119 neuropathy Diseases 0.000 claims description 4
• 230000007823 neuropathy Effects 0.000 claims description 4
• 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 4
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 4
• 230000008447 perception Effects 0.000 claims description 4
• 208000033300 perinatal asphyxia Diseases 0.000 claims description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
• 230000001107 psychogenic effect Effects 0.000 claims description 4
• 230000011514 reflex Effects 0.000 claims description 4
• 230000000698 schizophrenic effect Effects 0.000 claims description 4
• 208000012672 seasonal affective disease Diseases 0.000 claims description 4
• 230000001568 sexual effect Effects 0.000 claims description 4
• 201000009032 substance abuse Diseases 0.000 claims description 4
• 231100000736 substance abuse Toxicity 0.000 claims description 4
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
• 230000001755 vocal effect Effects 0.000 claims description 4
• JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 3
• WCHMYCOJRHCHAK-UHFFFAOYSA-N 2-(2-bromo-5-fluorophenyl)ethanol Chemical compound OCCC1=CC(F)=CC=C1Br WCHMYCOJRHCHAK-UHFFFAOYSA-N 0.000 claims description 3
• 208000008811 Agoraphobia Diseases 0.000 claims description 3
• 208000007415 Anhedonia Diseases 0.000 claims description 3
• 206010070530 Benign rolandic epilepsy Diseases 0.000 claims description 3
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 3
• 208000009132 Catalepsy Diseases 0.000 claims description 3
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 3
• 208000024254 Delusional disease Diseases 0.000 claims description 3
• 206010012374 Depressed mood Diseases 0.000 claims description 3
• 206010016845 Foetal alcohol syndrome Diseases 0.000 claims description 3
• 208000034308 Grand mal convulsion Diseases 0.000 claims description 3
• 206010022520 Intention tremor Diseases 0.000 claims description 3
• 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims description 3
• 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims description 3
• 206010033664 Panic attack Diseases 0.000 claims description 3
• 206010033799 Paralysis Diseases 0.000 claims description 3
• 208000004983 Phantom Limb Diseases 0.000 claims description 3
• 206010056238 Phantom pain Diseases 0.000 claims description 3
• 206010034912 Phobia Diseases 0.000 claims description 3
• 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 3
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 3
• 208000006289 Rett Syndrome Diseases 0.000 claims description 3
• 208000004974 Rolandic Epilepsy Diseases 0.000 claims description 3
• 208000000810 Separation Anxiety Diseases 0.000 claims description 3
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 3
• 206010047700 Vomiting Diseases 0.000 claims description 3
• 206010047853 Waxy flexibility Diseases 0.000 claims description 3
• 208000003554 absence epilepsy Diseases 0.000 claims description 3
• 208000026345 acute stress disease Diseases 0.000 claims description 3
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
• 230000006986 amnesia Effects 0.000 claims description 3
• 230000037007 arousal Effects 0.000 claims description 3
• 210000004227 basal ganglia Anatomy 0.000 claims description 3
• 208000013404 behavioral symptom Diseases 0.000 claims description 3
• 201000008916 benign epilepsy with centrotemporal spikes Diseases 0.000 claims description 3
• 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 3
• 208000024825 childhood disintegrative disease Diseases 0.000 claims description 3
• 208000033205 childhood epilepsy with centrotemporal spikes Diseases 0.000 claims description 3
• 230000007423 decrease Effects 0.000 claims description 3
• 208000002173 dizziness Diseases 0.000 claims description 3
• 230000001544 dysphoric effect Effects 0.000 claims description 3
• 206010016256 fatigue Diseases 0.000 claims description 3
• 208000026934 fetal alcohol spectrum disease Diseases 0.000 claims description 3
• 201000007794 fetal alcohol syndrome Diseases 0.000 claims description 3
• 230000002068 genetic effect Effects 0.000 claims description 3
• 208000013403 hyperactivity Diseases 0.000 claims description 3
• 230000000147 hypnotic effect Effects 0.000 claims description 3
• 201000003723 learning disability Diseases 0.000 claims description 3
• 230000037023 motor activity Effects 0.000 claims description 3
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
• 230000002151 myoclonic effect Effects 0.000 claims description 3
• 230000000422 nocturnal effect Effects 0.000 claims description 3
• 230000001575 pathological effect Effects 0.000 claims description 3
• 201000001204 progressive myoclonus epilepsy Diseases 0.000 claims description 3
• 125000006239 protecting group Chemical group 0.000 claims description 3
• 208000026961 psychosexual disease Diseases 0.000 claims description 3
• 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims description 3
• 208000025874 separation anxiety disease Diseases 0.000 claims description 3
• 201000001716 specific phobia Diseases 0.000 claims description 3
• 238000001228 spectrum Methods 0.000 claims description 3
• 230000035882 stress Effects 0.000 claims description 3
• 230000002739 subcortical effect Effects 0.000 claims description 3
• 230000009182 swimming Effects 0.000 claims description 3
• 230000001052 transient effect Effects 0.000 claims description 3
• 230000001457 vasomotor Effects 0.000 claims description 3
• 230000008673 vomiting Effects 0.000 claims description 3
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
• 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 2
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
• 208000030507 AIDS Diseases 0.000 claims description 2
• 206010052075 Acquired epileptic aphasia Diseases 0.000 claims description 2
• 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 2
• 241001047040 Agnosia Species 0.000 claims description 2
• 208000011403 Alexander disease Diseases 0.000 claims description 2
• 206010002820 Antisocial behaviour Diseases 0.000 claims description 2
• 102000007371 Ataxin-3 Human genes 0.000 claims description 2
• 102000014461 Ataxins Human genes 0.000 claims description 2
• 108010078286 Ataxins Proteins 0.000 claims description 2
• 208000009017 Athetosis Diseases 0.000 claims description 2
• 208000034577 Benign intracranial hypertension Diseases 0.000 claims description 2
• 206010048962 Brain oedema Diseases 0.000 claims description 2
• 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims description 2
• 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
• 206010058019 Cancer Pain Diseases 0.000 claims description 2
• 201000001601 Capgras syndrome Diseases 0.000 claims description 2
• 206010064012 Central pain syndrome Diseases 0.000 claims description 2
• 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
• 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 claims description 2
• 201000006867 Charcot-Marie-Tooth disease type 4 Diseases 0.000 claims description 2
• 201000001913 Childhood absence epilepsy Diseases 0.000 claims description 2
• 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 2
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
• 206010011878 Deafness Diseases 0.000 claims description 2
• 206010012245 Delusion of replacement Diseases 0.000 claims description 2
• 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
• 206010054089 Depressive symptom Diseases 0.000 claims description 2
• 208000001495 Disorganized Schizophrenia Diseases 0.000 claims description 2
• 201000007547 Dravet syndrome Diseases 0.000 claims description 2
• 206010049096 Dysmorphophobia Diseases 0.000 claims description 2
• 206010013976 Dyspraxia Diseases 0.000 claims description 2
• 208000016132 Epilepsy with myoclonic absences Diseases 0.000 claims description 2
• 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
• 208000035874 Excoriation Diseases 0.000 claims description 2
• 206010070246 Executive dysfunction Diseases 0.000 claims description 2
• 206010016059 Facial pain Diseases 0.000 claims description 2
• 208000002091 Febrile Seizures Diseases 0.000 claims description 2
• 208000001836 Firesetting Behavior Diseases 0.000 claims description 2
• 208000010235 Food Addiction Diseases 0.000 claims description 2
• 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
• 208000003078 Generalized Epilepsy Diseases 0.000 claims description 2
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
• 201000005569 Gout Diseases 0.000 claims description 2
• 208000014901 Graham Little-Piccardi-Lassueur syndrome Diseases 0.000 claims description 2
• 206010019468 Hemiplegia Diseases 0.000 claims description 2
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
• 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 claims description 2
• 206010063629 Hippocampal sclerosis Diseases 0.000 claims description 2
• 208000014513 Hoarding disease Diseases 0.000 claims description 2
• 208000000269 Hyperkinesis Diseases 0.000 claims description 2
• 206010020772 Hypertension Diseases 0.000 claims description 2
• 206010020928 Hypnopompic hallucination Diseases 0.000 claims description 2
• 208000018127 Idiopathic intracranial hypertension Diseases 0.000 claims description 2
• 206010021703 Indifference Diseases 0.000 claims description 2
• 206010021750 Infantile Spasms Diseases 0.000 claims description 2
• 208000035899 Infantile spasms syndrome Diseases 0.000 claims description 2
• 206010050296 Intervertebral disc protrusion Diseases 0.000 claims description 2
• 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 claims description 2
• 201000002832 Lewy body dementia Diseases 0.000 claims description 2
• 206010050219 Lumbar radiculopathy Diseases 0.000 claims description 2
• 208000016604 Lyme disease Diseases 0.000 claims description 2
• 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
• 208000037490 Medically Unexplained Symptoms Diseases 0.000 claims description 2
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 2
• 208000000060 Migraine with aura Diseases 0.000 claims description 2
• 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 2
• 208000007101 Muscle Cramp Diseases 0.000 claims description 2
• 208000010428 Muscle Weakness Diseases 0.000 claims description 2
• 208000029578 Muscle disease Diseases 0.000 claims description 2
• 206010028347 Muscle twitching Diseases 0.000 claims description 2
• 208000021642 Muscular disease Diseases 0.000 claims description 2
• 206010028372 Muscular weakness Diseases 0.000 claims description 2
• 206010028403 Mutism Diseases 0.000 claims description 2
• 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 2
• 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims description 2
• 208000005890 Neuroma Diseases 0.000 claims description 2
• 206010029412 Nightmare Diseases 0.000 claims description 2
• 208000012075 Paroxysmal dystonia Diseases 0.000 claims description 2
• 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
• 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
• 208000008713 Piriformis Muscle Syndrome Diseases 0.000 claims description 2
• 206010036313 Post-traumatic headache Diseases 0.000 claims description 2
• 206010071366 Post-traumatic neck syndrome Diseases 0.000 claims description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
• 201000009916 Postpartum depression Diseases 0.000 claims description 2
• 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
• 208000024777 Prion disease Diseases 0.000 claims description 2
• 208000014370 Psychogenic movement disease Diseases 0.000 claims description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 claims description 2
• 206010059604 Radicular pain Diseases 0.000 claims description 2
• 208000028665 Reactive Attachment disease Diseases 0.000 claims description 2
• 206010053632 Reactive psychosis Diseases 0.000 claims description 2
• 206010038743 Restlessness Diseases 0.000 claims description 2
• 208000017442 Retinal disease Diseases 0.000 claims description 2
• 206010038923 Retinopathy Diseases 0.000 claims description 2
• 208000036753 Schizophrenia, disorganised type Diseases 0.000 claims description 2
• 208000008039 Secondary Parkinson Disease Diseases 0.000 claims description 2
• 206010039917 Selective mutism Diseases 0.000 claims description 2
• 208000018642 Semantic dementia Diseases 0.000 claims description 2
• 206010039966 Senile dementia Diseases 0.000 claims description 2
• 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims description 2
• 206010041347 Somnambulism Diseases 0.000 claims description 2
• 208000005392 Spasm Diseases 0.000 claims description 2
• 208000014584 Specific learning disability Diseases 0.000 claims description 2
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
• 208000009205 Tinnitus Diseases 0.000 claims description 2
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
• 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 2
• 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
• 206010063661 Vascular encephalopathy Diseases 0.000 claims description 2
• 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 2
• 201000006791 West syndrome Diseases 0.000 claims description 2
• 208000021567 Whiplash injury Diseases 0.000 claims description 2
• 208000018839 Wilson disease Diseases 0.000 claims description 2
• 208000011152 acquired idiopathic torsion dystonia Diseases 0.000 claims description 2
• 208000005298 acute pain Diseases 0.000 claims description 2
• 208000012826 adjustment disease Diseases 0.000 claims description 2
• 208000011916 alternating hemiplegia Diseases 0.000 claims description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
• 201000007201 aphasia Diseases 0.000 claims description 2
• 230000036528 appetite Effects 0.000 claims description 2
• 235000019789 appetite Nutrition 0.000 claims description 2
• 206010003074 arachnoiditis Diseases 0.000 claims description 2
• 208000025748 atypical depressive disease Diseases 0.000 claims description 2
• 230000002567 autonomic effect Effects 0.000 claims description 2
• 208000022266 body dysmorphic disease Diseases 0.000 claims description 2
• 208000006752 brain edema Diseases 0.000 claims description 2
• 208000029028 brain injury Diseases 0.000 claims description 2
• 206010008129 cerebral palsy Diseases 0.000 claims description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
• 201000002866 cervical dystonia Diseases 0.000 claims description 2
• 238000002512 chemotherapy Methods 0.000 claims description 2
• 208000022371 chronic pain syndrome Diseases 0.000 claims description 2
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 2
• 208000018912 cluster headache syndrome Diseases 0.000 claims description 2
• 230000001149 cognitive effect Effects 0.000 claims description 2
• 208000030251 communication disease Diseases 0.000 claims description 2
• 206010010121 compartment syndrome Diseases 0.000 claims description 2
• 208000015134 congenital hypothalamic hamartoma syndrome Diseases 0.000 claims description 2
• 210000001619 diaphragma pelvis Anatomy 0.000 claims description 2
• 206010013461 dissociative amnesia Diseases 0.000 claims description 2
• 208000009985 drug-induced dyskinesia Diseases 0.000 claims description 2
• 230000008482 dysregulation Effects 0.000 claims description 2
• 230000000632 dystonic effect Effects 0.000 claims description 2
• 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 claims description 2
• 230000001037 epileptic effect Effects 0.000 claims description 2
• 210000003414 extremity Anatomy 0.000 claims description 2
• 231100000040 eye damage Toxicity 0.000 claims description 2
• 208000011149 familial idiopathic torsion dystonia Diseases 0.000 claims description 2
• 208000004967 femoral neuropathy Diseases 0.000 claims description 2
• 201000002886 generalized dystonia Diseases 0.000 claims description 2
• 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 claims description 2
• 208000012285 hip pain Diseases 0.000 claims description 2
• 206010020765 hypersomnia Diseases 0.000 claims description 2
• 230000003483 hypokinetic effect Effects 0.000 claims description 2
• 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 claims description 2
• 201000001881 impotence Diseases 0.000 claims description 2
• 208000018197 inherited torticollis Diseases 0.000 claims description 2
• 208000014674 injury Diseases 0.000 claims description 2
• 208000015046 intermittent explosive disease Diseases 0.000 claims description 2
• 208000028867 ischemia Diseases 0.000 claims description 2
• 230000000366 juvenile effect Effects 0.000 claims description 2
• 206010023461 kleptomania Diseases 0.000 claims description 2
• 208000024765 knee pain Diseases 0.000 claims description 2
• 201000010901 lateral sclerosis Diseases 0.000 claims description 2
• 230000000938 luteal effect Effects 0.000 claims description 2
• 208000002780 macular degeneration Diseases 0.000 claims description 2
• 201000003995 melancholia Diseases 0.000 claims description 2
• 208000005264 motor neuron disease Diseases 0.000 claims description 2
• 201000005545 motor peripheral neuropathy Diseases 0.000 claims description 2
• 208000019382 nerve compression syndrome Diseases 0.000 claims description 2
• 208000033510 neuroaxonal dystrophy Diseases 0.000 claims description 2
• 230000003961 neuronal insult Effects 0.000 claims description 2
• 206010029410 night sweats Diseases 0.000 claims description 2
• 230000036565 night sweats Effects 0.000 claims description 2
• 208000001797 obstructive sleep apnea Diseases 0.000 claims description 2
• 201000002851 oromandibular dystonia Diseases 0.000 claims description 2
• 201000008482 osteoarthritis Diseases 0.000 claims description 2
• 208000024817 paranoid personality disease Diseases 0.000 claims description 2
• 230000035515 penetration Effects 0.000 claims description 2
• 230000000737 periodic effect Effects 0.000 claims description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 claims description 2
• 208000022821 personality disease Diseases 0.000 claims description 2
• 201000003040 photosensitive epilepsy Diseases 0.000 claims description 2
• 206010049433 piriformis syndrome Diseases 0.000 claims description 2
• 230000004793 poor memory Effects 0.000 claims description 2
• 210000002442 prefrontal cortex Anatomy 0.000 claims description 2
• 206010036596 premature ejaculation Diseases 0.000 claims description 2
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 2
• 201000008752 progressive muscular atrophy Diseases 0.000 claims description 2
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
• 201000000196 pseudobulbar palsy Diseases 0.000 claims description 2
• 208000001381 pseudotumor cerebri Diseases 0.000 claims description 2
• 201000004645 pyromania Diseases 0.000 claims description 2
• 208000019969 rapid eye movement sleep disease Diseases 0.000 claims description 2
• 201000005070 reflex epilepsy Diseases 0.000 claims description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
• 231100000241 scar Toxicity 0.000 claims description 2
• 206010039722 scoliosis Diseases 0.000 claims description 2
• 230000035945 sensitivity Effects 0.000 claims description 2
• 208000033914 shift work type circadian rhythm sleep disease Diseases 0.000 claims description 2
• 230000019491 signal transduction Effects 0.000 claims description 2
• 230000011273 social behavior Effects 0.000 claims description 2
• 230000001148 spastic effect Effects 0.000 claims description 2
• 210000001032 spinal nerve Anatomy 0.000 claims description 2
• 208000005809 status epilepticus Diseases 0.000 claims description 2
• 230000036262 stenosis Effects 0.000 claims description 2
• 208000037804 stenosis Diseases 0.000 claims description 2
• 201000006152 substance dependence Diseases 0.000 claims description 2
• 230000002889 sympathetic effect Effects 0.000 claims description 2
• 210000003478 temporal lobe Anatomy 0.000 claims description 2
• 201000008914 temporal lobe epilepsy Diseases 0.000 claims description 2
• 231100000886 tinnitus Toxicity 0.000 claims description 2
• 230000008733 trauma Effects 0.000 claims description 2
• 230000009529 traumatic brain injury Effects 0.000 claims description 2
• 208000002271 trichotillomania Diseases 0.000 claims description 2
• 230000002792 vascular Effects 0.000 claims description 2
• 208000009935 visceral pain Diseases 0.000 claims description 2
• 230000031836 visual learning Effects 0.000 claims description 2
• 230000003936 working memory Effects 0.000 claims description 2
• 150000002431 hydrogen Chemical group 0.000 claims 12
• 208000027626 Neurocognitive disease Diseases 0.000 claims 5
• 206010027175 memory impairment Diseases 0.000 claims 3
• 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims 2
• 101100310222 Caenorhabditis briggsae she-1 gene Proteins 0.000 claims 2
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 2
• 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 2
• 206010046543 Urinary incontinence Diseases 0.000 claims 2
• 230000007812 deficiency Effects 0.000 claims 2
• 238000010511 deprotection reaction Methods 0.000 claims 2
• 230000003993 interaction Effects 0.000 claims 2
• 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims 2
• 206010058504 Ballismus Diseases 0.000 claims 1
• 101100001231 Caenorhabditis elegans aha-1 gene Proteins 0.000 claims 1
• 241000282461 Canis lupus Species 0.000 claims 1
• 208000009810 Catatonic Schizophrenia Diseases 0.000 claims 1
• 208000000094 Chronic Pain Diseases 0.000 claims 1
• 206010013142 Disinhibition Diseases 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 206010018498 Goitre Diseases 0.000 claims 1
• 206010018671 Grandiosity Diseases 0.000 claims 1
• 208000030990 Impulse-control disease Diseases 0.000 claims 1
• 206010024264 Lethargy Diseases 0.000 claims 1
• 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
• 208000008238 Muscle Spasticity Diseases 0.000 claims 1
• 101800001775 Nuclear inclusion protein A Proteins 0.000 claims 1
• 208000009144 Pure autonomic failure Diseases 0.000 claims 1
• 208000036754 Schizophrenia, catatonic type Diseases 0.000 claims 1
• 208000036752 Schizophrenia, paranoid type Diseases 0.000 claims 1
• 208000013058 Weber syndrome Diseases 0.000 claims 1
• 230000002917 arthritic effect Effects 0.000 claims 1
• 208000003464 asthenopia Diseases 0.000 claims 1
• 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 claims 1
• 201000002922 basal ganglia calcification Diseases 0.000 claims 1
• 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 claims 1
• 201000007293 brain stem infarction Diseases 0.000 claims 1
• 230000006999 cognitive decline Effects 0.000 claims 1
• JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims 1
• 230000002920 convulsive effect Effects 0.000 claims 1
• 230000006866 deterioration Effects 0.000 claims 1
• 230000002964 excitative effect Effects 0.000 claims 1
• 230000004761 fibrosis Effects 0.000 claims 1
• 201000003872 goiter Diseases 0.000 claims 1
• 230000010370 hearing loss Effects 0.000 claims 1
• 231100000888 hearing loss Toxicity 0.000 claims 1
• 208000011110 idiopathic torsion dystonia Diseases 0.000 claims 1
• 230000009191 jumping Effects 0.000 claims 1
• 230000003387 muscular Effects 0.000 claims 1
• 210000005036 nerve Anatomy 0.000 claims 1
• 230000001537 neural effect Effects 0.000 claims 1
• 230000002981 neuropathic effect Effects 0.000 claims 1
• 230000001936 parietal effect Effects 0.000 claims 1
• 230000001314 paroxysmal effect Effects 0.000 claims 1
• 208000013623 stereotypic movement disease Diseases 0.000 claims 1
• 208000018724 torsion dystonia Diseases 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 130
• 238000005160 1H NMR spectroscopy Methods 0.000 description 95
• 239000000243 solution Substances 0.000 description 90
• 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 75
• 238000002360 preparation method Methods 0.000 description 58
• 235000019439 ethyl acetate Nutrition 0.000 description 56
• 238000007429 general method Methods 0.000 description 52
• 239000007787 solid Substances 0.000 description 51
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 47
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
• 239000003921 oil Substances 0.000 description 44
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 34
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
• 239000003208 petroleum Substances 0.000 description 28
• 239000012071 phase Substances 0.000 description 28
• HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 27
• 238000004296 chiral HPLC Methods 0.000 description 27
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
• 239000012044 organic layer Substances 0.000 description 26
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 22
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
• 239000002904 solvent Substances 0.000 description 20
• 239000003795 chemical substances by application Substances 0.000 description 19
• 238000003818 flash chromatography Methods 0.000 description 19
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 18
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 18
• 238000000746 purification Methods 0.000 description 18
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 18
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
• 239000000935 antidepressant agent Substances 0.000 description 16
• 229940005513 antidepressants Drugs 0.000 description 16
• 239000012230 colorless oil Substances 0.000 description 16
• 229940124597 therapeutic agent Drugs 0.000 description 16
• 230000014759 maintenance of location Effects 0.000 description 15
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 14
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 13
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
• 239000011541 reaction mixture Substances 0.000 description 13
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 13
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
• 238000004587 chromatography analysis Methods 0.000 description 12
• UFEJKYYYVXYMMS-UHFFFAOYSA-N methylcarbamic acid Chemical compound CNC(O)=O UFEJKYYYVXYMMS-UHFFFAOYSA-N 0.000 description 12
• 229920006395 saturated elastomer Polymers 0.000 description 12
• 239000000741 silica gel Substances 0.000 description 12
• 229910002027 silica gel Inorganic materials 0.000 description 12
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
• 229940025084 amphetamine Drugs 0.000 description 11
• 239000012043 crude product Substances 0.000 description 11
• 229910052938 sodium sulfate Inorganic materials 0.000 description 11
• 235000011152 sodium sulphate Nutrition 0.000 description 11
• 239000004698 Polyethylene Substances 0.000 description 10
• 125000003545 alkoxy group Chemical group 0.000 description 10
• 239000000164 antipsychotic agent Substances 0.000 description 10
• 238000004128 high performance liquid chromatography Methods 0.000 description 10
• 239000012074 organic phase Substances 0.000 description 10
• 238000002560 therapeutic procedure Methods 0.000 description 10
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 9
• QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 9
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 9
• 241000282414 Homo sapiens Species 0.000 description 9
• 241001465754 Metazoa Species 0.000 description 9
• 238000005481 NMR spectroscopy Methods 0.000 description 9
• 229910021529 ammonia Inorganic materials 0.000 description 9
• 125000003118 aryl group Chemical group 0.000 description 9
• 125000004432 carbon atom Chemical group C* 0.000 description 9
• 239000000706 filtrate Substances 0.000 description 9
• 125000000623 heterocyclic group Chemical group 0.000 description 9
• 239000010410 layer Substances 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 8
• 239000002552 dosage form Substances 0.000 description 8
• 150000003840 hydrochlorides Chemical class 0.000 description 8
• 239000005457 ice water Substances 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 7
• 239000002249 anxiolytic agent Substances 0.000 description 7
• 229960001078 lithium Drugs 0.000 description 7
• 229910052744 lithium Inorganic materials 0.000 description 7
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 7
• SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 7
• DPGSPRJLAZGUBQ-UHFFFAOYSA-N 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 6
• 206010026749 Mania Diseases 0.000 description 6
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
• 238000000540 analysis of variance Methods 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 229940005529 antipsychotics Drugs 0.000 description 6
• 239000008346 aqueous phase Substances 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 239000011575 calcium Substances 0.000 description 6
• 239000003112 inhibitor Substances 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 239000000543 intermediate Substances 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 125000001424 substituent group Chemical group 0.000 description 6
• FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 6
• RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 5
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
• 102000010909 Monoamine Oxidase Human genes 0.000 description 5
• 108010062431 Monoamine oxidase Proteins 0.000 description 5
• 230000000561 anti-psychotic effect Effects 0.000 description 5
• 230000000949 anxiolytic effect Effects 0.000 description 5
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
• 229910052794 bromium Inorganic materials 0.000 description 5
• 208000037765 diseases and disorders Diseases 0.000 description 5
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 5
• 238000010829 isocratic elution Methods 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• IXFIRBDJVKBOFO-UHFFFAOYSA-N 3,4-dihydro-1h-isochromen-4-ol Chemical compound C1=CC=C2C(O)COCC2=C1 IXFIRBDJVKBOFO-UHFFFAOYSA-N 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 102000014150 Interferons Human genes 0.000 description 4
• 108010050904 Interferons Proteins 0.000 description 4
• 239000002841 Lewis acid Substances 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 230000001430 anti-depressive effect Effects 0.000 description 4
• 150000001555 benzenes Chemical class 0.000 description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 150000004768 bromobenzenes Chemical class 0.000 description 4
• 229910052799 carbon Inorganic materials 0.000 description 4
• 229960003920 cocaine Drugs 0.000 description 4
• 238000004440 column chromatography Methods 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• 125000003709 fluoroalkyl group Chemical group 0.000 description 4
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
• 230000035863 hyperlocomotion Effects 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 150000007517 lewis acids Chemical class 0.000 description 4
• AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 description 4
• OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
• GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 4
• 230000001962 neuropharmacologic effect Effects 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• 239000003368 psychostimulant agent Substances 0.000 description 4
• 238000010791 quenching Methods 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 241000894007 species Species 0.000 description 4
• MSWTVSDFEYSRMQ-UHFFFAOYSA-N tert-butyl n-methyl-n-(2-oxoethyl)carbamate Chemical compound O=CCN(C)C(=O)OC(C)(C)C MSWTVSDFEYSRMQ-UHFFFAOYSA-N 0.000 description 4
• RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• HAKYKQWZRSPYAR-UHFFFAOYSA-N 2-(2-bromo-5-chlorophenyl)ethanol Chemical compound OCCC1=CC(Cl)=CC=C1Br HAKYKQWZRSPYAR-UHFFFAOYSA-N 0.000 description 3
• HNIGZVZDWCTFPR-UHFFFAOYSA-N 2-(2-fluorophenyl)ethanol Chemical compound OCCC1=CC=CC=C1F HNIGZVZDWCTFPR-UHFFFAOYSA-N 0.000 description 3
• LYIIBVSRGJSHAV-UHFFFAOYSA-N 2-aminoacetaldehyde Chemical compound NCC=O LYIIBVSRGJSHAV-UHFFFAOYSA-N 0.000 description 3
• 241000283725 Bos Species 0.000 description 3
• QVMPRHLPDNVERE-UHFFFAOYSA-N BrC1=CC(=CC=2CCOC=21)CCO Chemical compound BrC1=CC(=CC=2CCOC=21)CCO QVMPRHLPDNVERE-UHFFFAOYSA-N 0.000 description 3
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 3
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 3
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
• 229940005530 anxiolytics Drugs 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 208000028683 bipolar I disease Diseases 0.000 description 3
• 229960002802 bromocriptine Drugs 0.000 description 3
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000013058 crude material Substances 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 3
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 238000012048 forced swim test Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 125000004438 haloalkoxy group Chemical group 0.000 description 3
• 125000001183 hydrocarbyl group Chemical group 0.000 description 3
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
• 229940047124 interferons Drugs 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 239000012299 nitrogen atmosphere Substances 0.000 description 3
• 239000008177 pharmaceutical agent Substances 0.000 description 3
• 229950010883 phencyclidine Drugs 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 229960003089 pramipexole Drugs 0.000 description 3
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 150000003254 radicals Chemical class 0.000 description 3
• 229940044551 receptor antagonist Drugs 0.000 description 3
• 239000002464 receptor antagonist Substances 0.000 description 3
• 229910001961 silver nitrate Inorganic materials 0.000 description 3
• 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
• IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 2
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
• VWTRQZQYASNOGM-UHFFFAOYSA-N 1,3-dimethoxy-n-methylpropan-2-amine Chemical compound COCC(NC)COC VWTRQZQYASNOGM-UHFFFAOYSA-N 0.000 description 2
• XCJUTYWWVUHCGL-UHFFFAOYSA-N 2-(1,3-dihydro-2-benzofuran-5-yl)ethanol Chemical compound OCCC1=CC=C2COCC2=C1 XCJUTYWWVUHCGL-UHFFFAOYSA-N 0.000 description 2
• HXHFPLLPFMVPFV-UHFFFAOYSA-N 2-(2-bromo-5-methylphenyl)ethanol Chemical compound CC1=CC=C(Br)C(CCO)=C1 HXHFPLLPFMVPFV-UHFFFAOYSA-N 0.000 description 2
• ZHYZZBGVWDYSEW-UHFFFAOYSA-N 2-(2-bromophenyl)oxirane Chemical compound BrC1=CC=CC=C1C1OC1 ZHYZZBGVWDYSEW-UHFFFAOYSA-N 0.000 description 2
• RUGISKODRCWQNE-UHFFFAOYSA-N 2-(2-methylphenyl)ethanol Chemical compound CC1=CC=CC=C1CCO RUGISKODRCWQNE-UHFFFAOYSA-N 0.000 description 2
• MZNBGEKFZCWVES-UHFFFAOYSA-N 2-(3-fluorophenyl)ethanol Chemical compound OCCC1=CC=CC(F)=C1 MZNBGEKFZCWVES-UHFFFAOYSA-N 0.000 description 2
• KAAZJHHCNNJCJZ-UHFFFAOYSA-N 2-(6-bromo-1,3-dihydro-2-benzofuran-5-yl)ethanol Chemical compound BrC1=C(C=C2COCC2=C1)CCO KAAZJHHCNNJCJZ-UHFFFAOYSA-N 0.000 description 2
• WYWUIYMLVFQUCU-UHFFFAOYSA-N 3,4-dihydro-1h-isochromene-8-carbonitrile Chemical compound C1COCC2=C1C=CC=C2C#N WYWUIYMLVFQUCU-UHFFFAOYSA-N 0.000 description 2
• PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 2
• KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
• XXXJBFHPAKVMCM-UHFFFAOYSA-N 4-chloro-1,3-dihydro-2-benzofuran-1-ol Chemical compound ClC1=C2COC(C2=CC=C1)O XXXJBFHPAKVMCM-UHFFFAOYSA-N 0.000 description 2
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
• LQTALFFPGUPAAA-UHFFFAOYSA-N 5-ethenyl-1,3-dihydro-2-benzofuran Chemical compound C=CC1=CC=C2COCC2=C1 LQTALFFPGUPAAA-UHFFFAOYSA-N 0.000 description 2
• 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
• 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• TWUJBHBRYYTEDL-UHFFFAOYSA-N Alentemol Chemical compound OC1=CC(CC(N(CCC)CCC)C2)=C3C2=CC=CC3=C1 TWUJBHBRYYTEDL-UHFFFAOYSA-N 0.000 description 2
• 229940124810 Alzheimer's drug Drugs 0.000 description 2
• 241000272517 Anseriformes Species 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• QUTHENPVLJQDLG-UHFFFAOYSA-N CC1(CB(CC1(C)C)C=C)C Chemical compound CC1(CB(CC1(C)C)C=C)C QUTHENPVLJQDLG-UHFFFAOYSA-N 0.000 description 2
• 208000011597 CGF1 Diseases 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
• PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
• 208000012202 Pervasive developmental disease Diseases 0.000 description 2
• 241000286209 Phasianidae Species 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 206010062519 Poor quality sleep Diseases 0.000 description 2
• 206010037180 Psychiatric symptoms Diseases 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• 125000004945 acylaminoalkyl group Chemical group 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 229950007263 alentemol Drugs 0.000 description 2
• 125000003342 alkenyl group Chemical group 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 150000001412 amines Chemical group 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 230000007131 anti Alzheimer effect Effects 0.000 description 2
• 229940035678 anti-parkinson drug Drugs 0.000 description 2
• 229940125681 anticonvulsant agent Drugs 0.000 description 2
• 239000001961 anticonvulsive agent Substances 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 150000001499 aryl bromides Chemical class 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 239000003693 atypical antipsychotic agent Substances 0.000 description 2
• 229940127236 atypical antipsychotics Drugs 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 125000005605 benzo group Chemical group 0.000 description 2
• 229940049706 benzodiazepine Drugs 0.000 description 2
• 150000001557 benzodiazepines Chemical class 0.000 description 2
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
• 208000022257 bipolar II disease Diseases 0.000 description 2
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
• 229960000623 carbamazepine Drugs 0.000 description 2
• 229960004205 carbidopa Drugs 0.000 description 2
• TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 239000000812 cholinergic antagonist Substances 0.000 description 2
• 239000000544 cholinesterase inhibitor Substances 0.000 description 2
• 229960001653 citalopram Drugs 0.000 description 2
• 229960004362 clorazepate Drugs 0.000 description 2
• XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 2
• 229960004170 clozapine Drugs 0.000 description 2
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
• 229960003914 desipramine Drugs 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 238000013504 emergency use authorization Methods 0.000 description 2
• JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 2
• 229960003337 entacapone Drugs 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 229960002464 fluoxetine Drugs 0.000 description 2
• 235000019256 formaldehyde Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
• 229960003878 haloperidol Drugs 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• 229960003162 iloperidone Drugs 0.000 description 2
• XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 2
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 125000004250 isochroman-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])OC2([H])* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 229960003299 ketamine Drugs 0.000 description 2
• 229960001848 lamotrigine Drugs 0.000 description 2
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 2
• 229960003587 lisuride Drugs 0.000 description 2
• 230000003137 locomotive effect Effects 0.000 description 2
• 229940126601 medicinal product Drugs 0.000 description 2
• 230000003923 mental ability Effects 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• DJPMKHBXSUGMGA-UHFFFAOYSA-N methyl 2-(2,3-dihydro-1-benzofuran-5-yl)acetate Chemical compound COC(=O)CC1=CC=C2OCCC2=C1 DJPMKHBXSUGMGA-UHFFFAOYSA-N 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 229960002715 nicotine Drugs 0.000 description 2
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
• 229960005017 olanzapine Drugs 0.000 description 2
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229960001057 paliperidone Drugs 0.000 description 2
• UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 229960004851 pergolide Drugs 0.000 description 2
• YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
• 229960000762 perphenazine Drugs 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• QARVLSVVCXYDNA-UHFFFAOYSA-N phenyl bromide Natural products BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 229960003300 pimavanserin Drugs 0.000 description 2
• RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 239000002574 poison Substances 0.000 description 2
• 231100000614 poison Toxicity 0.000 description 2
• 238000012746 preparative thin layer chromatography Methods 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 230000000171 quenching effect Effects 0.000 description 2
• 230000004461 rapid eye movement Effects 0.000 description 2
• 230000003252 repetitive effect Effects 0.000 description 2
• 229960001534 risperidone Drugs 0.000 description 2
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
• 229960003946 selegiline Drugs 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 230000004039 social cognition Effects 0.000 description 2
• 230000003997 social interaction Effects 0.000 description 2
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
• 229960001940 sulfasalazine Drugs 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• OEQRZPWMXXJEKU-UHFFFAOYSA-N tert-butyl n-(1-oxopropan-2-yl)carbamate Chemical compound O=CC(C)NC(=O)OC(C)(C)C OEQRZPWMXXJEKU-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 2
• 229960001918 tiagabine Drugs 0.000 description 2
• MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 2
• 229960004603 tolcapone Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 229960003741 tranylcypromine Drugs 0.000 description 2
• PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
• 229960003991 trazodone Drugs 0.000 description 2
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
• 229960000604 valproic acid Drugs 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• 239000001815 (2R)-2-phenylpropan-1-ol Substances 0.000 description 1
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
• YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
• MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
• NPCQNMZQZFGCGK-UHFFFAOYSA-N (4-chloro-1,3-dihydro-2-benzofuran-1-yl)methanamine Chemical compound ClC1=C2COC(C2=CC=C1)CN NPCQNMZQZFGCGK-UHFFFAOYSA-N 0.000 description 1
• GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
• VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
• TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
• NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical compound B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 description 1
• FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
• BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
• LALSYIKKTXUSLG-UHFFFAOYSA-N 2-(2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OCCC2=C1 LALSYIKKTXUSLG-UHFFFAOYSA-N 0.000 description 1
• WIOQRCFOUIBCEB-UHFFFAOYSA-N 2-(2,5-difluorophenyl)ethanol Chemical compound OCCC1=CC(F)=CC=C1F WIOQRCFOUIBCEB-UHFFFAOYSA-N 0.000 description 1
• WZSFMLUUUZHQLN-UHFFFAOYSA-N 2-(2-bromo-3-fluorophenyl)oxirane Chemical compound BrC1=C(C=CC=C1F)C1OC1 WZSFMLUUUZHQLN-UHFFFAOYSA-N 0.000 description 1
• AVHIUBUCWYRMQV-UHFFFAOYSA-N 2-(2-bromo-4-fluorophenyl)ethanol Chemical compound OCCC1=CC=C(F)C=C1Br AVHIUBUCWYRMQV-UHFFFAOYSA-N 0.000 description 1
• ADLOWZRDUHSVRU-UHFFFAOYSA-N 2-(2-bromophenyl)ethanol Chemical compound OCCC1=CC=CC=C1Br ADLOWZRDUHSVRU-UHFFFAOYSA-N 0.000 description 1
• IWNHTCBFRSCBQK-UHFFFAOYSA-N 2-(2-chlorophenyl)ethanol Chemical compound OCCC1=CC=CC=C1Cl IWNHTCBFRSCBQK-UHFFFAOYSA-N 0.000 description 1
• XLDRDNQLEMMNNH-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethanol Chemical compound COC1=CC=CC=C1CCO XLDRDNQLEMMNNH-UHFFFAOYSA-N 0.000 description 1
• NDWAVJKRSASRPH-UHFFFAOYSA-N 2-(3-chlorophenyl)ethanol Chemical compound OCCC1=CC=CC(Cl)=C1 NDWAVJKRSASRPH-UHFFFAOYSA-N 0.000 description 1
• HZFRKZWBVUJYDA-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanol Chemical compound OCCC1=CC=C(Cl)C=C1 HZFRKZWBVUJYDA-UHFFFAOYSA-N 0.000 description 1
• CWONQYXCGBTASW-UHFFFAOYSA-N 2-(5-bromo-2-fluorophenyl)ethanol Chemical compound OCCC1=CC(Br)=CC=C1F CWONQYXCGBTASW-UHFFFAOYSA-N 0.000 description 1
• FHRKVRDNKBOYTD-UHFFFAOYSA-N 2-(7-bromo-2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound BrC1=CC(CC(=O)O)=CC2=C1OCC2 FHRKVRDNKBOYTD-UHFFFAOYSA-N 0.000 description 1
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
• YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
• DBKIEXOOUXQPGC-UHFFFAOYSA-N 2-[2-(trifluoromethyl)phenyl]ethanol Chemical compound OCCC1=CC=CC=C1C(F)(F)F DBKIEXOOUXQPGC-UHFFFAOYSA-N 0.000 description 1
• OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• WTGUAUVAXDZHJX-UHFFFAOYSA-N 2-chloro-2-phenylethanol Chemical compound OCC(Cl)C1=CC=CC=C1 WTGUAUVAXDZHJX-UHFFFAOYSA-N 0.000 description 1
• BFDWJJVVEYQXTI-UHFFFAOYSA-N 2-ethenyl-1,3,2-dioxaborolane Chemical compound C=CB1OCCO1 BFDWJJVVEYQXTI-UHFFFAOYSA-N 0.000 description 1
• ZVSCENGNXWPDPL-UHFFFAOYSA-N 2-methyl-2-phenylpropan-1-ol Chemical compound OCC(C)(C)C1=CC=CC=C1 ZVSCENGNXWPDPL-UHFFFAOYSA-N 0.000 description 1
• LQIIEHBULBHJKX-UHFFFAOYSA-N 2-methylpropylalumane Chemical compound CC(C)C[AlH2] LQIIEHBULBHJKX-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• NFNOAHXEQXMCGT-UHFFFAOYSA-N 2-phenylmethoxyacetaldehyde Chemical compound O=CCOCC1=CC=CC=C1 NFNOAHXEQXMCGT-UHFFFAOYSA-N 0.000 description 1
• ILJDAFPFCCVDKU-UHFFFAOYSA-N 3,4-dihydro-1h-isochromen-1-ylmethanamine Chemical class C1=CC=C2C(CN)OCCC2=C1 ILJDAFPFCCVDKU-UHFFFAOYSA-N 0.000 description 1
• APTJYJKYTJBTMY-UHFFFAOYSA-N 3-(2-bromo-3-fluorophenyl)propan-1-ol Chemical compound OCCCC1=CC=CC(F)=C1Br APTJYJKYTJBTMY-UHFFFAOYSA-N 0.000 description 1
• WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• YXRYUZZNZIECQB-UHFFFAOYSA-N 3-chloro-2-(hydroxymethyl)benzoic acid Chemical compound OCC1=C(Cl)C=CC=C1C(O)=O YXRYUZZNZIECQB-UHFFFAOYSA-N 0.000 description 1
• OJIYUFAIWHJJNL-UHFFFAOYSA-N 3-chloro-2-formylbenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1C=O OJIYUFAIWHJJNL-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• HOIIHACBCFLJET-SFTDATJTSA-N 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido-[3',4':4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7h)-yl)-1-(4-fluorophenyl)-1-butanone Chemical compound C([C@@H]1N2CCN(C=3C=CC=C(C2=3)[C@@H]1C1)C)CN1CCCC(=O)C1=CC=C(F)C=C1 HOIIHACBCFLJET-SFTDATJTSA-N 0.000 description 1
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
• USANFGVJSVCTPA-UHFFFAOYSA-N 4-chloro-1,3-dihydro-2-benzofuran-1-carbonitrile Chemical compound ClC1=C2COC(C2=CC=C1)C#N USANFGVJSVCTPA-UHFFFAOYSA-N 0.000 description 1
• MWUVGXCUHWKQJE-UHFFFAOYSA-N 4-fluorophenethyl alcohol Chemical compound OCCC1=CC=C(F)C=C1 MWUVGXCUHWKQJE-UHFFFAOYSA-N 0.000 description 1
• 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
• BWUAVKVDIHSNPD-UHFFFAOYSA-N 5-bromo-1,3-dihydro-2-benzofuran-1-ol Chemical compound BrC1=CC2=C(C(OC2)O)C=C1 BWUAVKVDIHSNPD-UHFFFAOYSA-N 0.000 description 1
• XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 206010001540 Akathisia Diseases 0.000 description 1
• 238000006412 Alper carbonylation reaction Methods 0.000 description 1
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
• 208000036640 Asperger disease Diseases 0.000 description 1
• 201000006062 Asperger syndrome Diseases 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 229940123208 Biguanide Drugs 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• KYLYRZCTVPAWOK-UHFFFAOYSA-N BrC1=C(C=CC=C1)C(CO[Si](C)(C)C(C)(C)C)(F)F Chemical compound BrC1=C(C=CC=C1)C(CO[Si](C)(C)C(C)(C)C)(F)F KYLYRZCTVPAWOK-UHFFFAOYSA-N 0.000 description 1
• 241000566113 Branta sandvicensis Species 0.000 description 1
• 208000021465 Brief psychotic disease Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
• FFFURALZLYNBGM-UHFFFAOYSA-N COC(CN(C(OC(C)(C)C)=O)C)OC Chemical compound COC(CN(C(OC(C)(C)C)=O)C)OC FFFURALZLYNBGM-UHFFFAOYSA-N 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 244000025254 Cannabis sativa Species 0.000 description 1
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• PTSBJGQLQVBLIT-UHFFFAOYSA-N ClC1COC(C2=CC=CC=C12)CN(C(OC(C)(C)C)=O)C Chemical compound ClC1COC(C2=CC=CC=C12)CN(C(OC(C)(C)C)=O)C PTSBJGQLQVBLIT-UHFFFAOYSA-N 0.000 description 1
• GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 101150088590 DHQS gene Proteins 0.000 description 1
• 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
• 206010012241 Delusion of grandeur Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 208000012239 Developmental disease Diseases 0.000 description 1
• WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
• 208000004483 Dyspareunia Diseases 0.000 description 1
• 208000008967 Enuresis Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
• 108010011459 Exenatide Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• CVKUMNRCIJMVAR-UHFFFAOYSA-N Fenoldopam mesylate Chemical compound CS(O)(=O)=O.C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 CVKUMNRCIJMVAR-UHFFFAOYSA-N 0.000 description 1
• PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 208000001914 Fragile X syndrome Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 229910004373 HOAc Inorganic materials 0.000 description 1
• 101150104779 HTR2A gene Proteins 0.000 description 1
• 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
• 101000992378 Homo sapiens Oxysterol-binding protein 2 Proteins 0.000 description 1
• 206010060800 Hot flush Diseases 0.000 description 1
• LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 206010021403 Illusion Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 208000017463 Infantile neuroaxonal dystrophy Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 201000006347 Intellectual Disability Diseases 0.000 description 1
• 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
• 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 241000581650 Ivesia Species 0.000 description 1
• 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
• 201000008189 Juvenile absence epilepsy Diseases 0.000 description 1
• 241000087799 Koma Species 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
• 208000020358 Learning disease Diseases 0.000 description 1
• LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
• YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
• 108010019598 Liraglutide Proteins 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 241000343235 Maso Species 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
• IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
• 101100498160 Mus musculus Dach1 gene Proteins 0.000 description 1
• 101100006982 Mus musculus Ppcdc gene Proteins 0.000 description 1
• 101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 1
• 101100049053 Mus musculus Vash1 gene Proteins 0.000 description 1
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
• YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 1
• AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
• 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
• KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
• 102100032164 Oxysterol-binding protein 2 Human genes 0.000 description 1
• 241001079606 Paches Species 0.000 description 1
• 240000000220 Panda oleosa Species 0.000 description 1
• 235000016496 Panda oleosa Nutrition 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034759 Petit mal epilepsy Diseases 0.000 description 1
• RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
• 229920005372 Plexiglas® Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 description 1
• 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
• 241000159610 Roya <green alga> Species 0.000 description 1
• 101000971782 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Oxysterol-binding protein homolog 4 Proteins 0.000 description 1
• 208000020186 Schizophreniform disease Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 206010039740 Screaming Diseases 0.000 description 1
• 206010070240 Sexually inappropriate behaviour Diseases 0.000 description 1
• 229910008455 Si—Ca Inorganic materials 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 206010042008 Stereotypy Diseases 0.000 description 1
• 208000010513 Stupor Diseases 0.000 description 1
• 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
• 208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 206010042458 Suicidal ideation Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 229940100389 Sulfonylurea Drugs 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 208000027522 Sydenham chorea Diseases 0.000 description 1
• 206010064805 Tachyphrenia Diseases 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
• 241000928104 Tetrias Species 0.000 description 1
• 244000299461 Theobroma cacao Species 0.000 description 1
• 235000009470 Theobroma cacao Nutrition 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 229940123464 Thiazolidinedione Drugs 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
• GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
• 208000006633 Tonic-Clonic Epilepsy Diseases 0.000 description 1
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
• 244000111306 Torreya nucifera Species 0.000 description 1
• 235000006732 Torreya nucifera Nutrition 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
• 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
• FEJCCPXHZHKTIL-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCC(F)(F)C1=C(C=CC=C1)C(CN(C(OC(C)(C)C)=O)C)O Chemical compound [Si](C)(C)(C(C)(C)C)OCC(F)(F)C1=C(C=CC=C1)C(CN(C(OC(C)(C)C)=O)C)O FEJCCPXHZHKTIL-UHFFFAOYSA-N 0.000 description 1
• 229960002632 acarbose Drugs 0.000 description 1
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• 229960001466 acetohexamide Drugs 0.000 description 1
• VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 229940121359 adenosine receptor antagonist Drugs 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 230000007000 age related cognitive decline Effects 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000000676 alkoxyimino group Chemical group 0.000 description 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
• 229960001667 alogliptin Drugs 0.000 description 1
• 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 229960004538 alprazolam Drugs 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000004103 aminoalkyl group Chemical group 0.000 description 1
• 229960003036 amisulpride Drugs 0.000 description 1
• NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 229960002519 amoxapine Drugs 0.000 description 1
• QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 230000003474 anti-emetic effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000002253 anti-ischaemic effect Effects 0.000 description 1
• 230000003561 anti-manic effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
• 229940125708 antidiabetic agent Drugs 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 229940125683 antiemetic agent Drugs 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
• 239000000063 antileukemic agent Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 229960004046 apomorphine Drugs 0.000 description 1
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
• ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
• 229960001372 aprepitant Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229960004372 aripiprazole Drugs 0.000 description 1
• 229960004823 armodafinil Drugs 0.000 description 1
• YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005245 asenapine Drugs 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 229960002430 atomoxetine Drugs 0.000 description 1
• VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
• 229960000911 benserazide Drugs 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 239000002439 beta secretase inhibitor Substances 0.000 description 1
• 150000004283 biguanides Chemical class 0.000 description 1
• 229920000080 bile acid sequestrant Polymers 0.000 description 1
• 229940096699 bile acid sequestrants Drugs 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
• 229960003003 biperiden Drugs 0.000 description 1
• 208000025307 bipolar depression Diseases 0.000 description 1
• SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
• 229910000085 borane Inorganic materials 0.000 description 1
• 238000006795 borylation reaction Methods 0.000 description 1
• 229960001210 brexpiprazole Drugs 0.000 description 1
• ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 description 1
• 229960002161 brivaracetam Drugs 0.000 description 1
• MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 description 1
• ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
• 229960003655 bromfenac Drugs 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 229960004111 buformin Drugs 0.000 description 1
• XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
• 229960001736 buprenorphine Drugs 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
• QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
• 229960002495 buspirone Drugs 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 229960004596 cabergoline Drugs 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 230000002308 calcification Effects 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 239000003557 cannabinoid Substances 0.000 description 1
• 229930003827 cannabinoid Natural products 0.000 description 1
• 229940065144 cannabinoids Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• ZJRWDIJRKKXMNW-UHFFFAOYSA-N carbonic acid;cobalt Chemical compound [Co].OC(O)=O ZJRWDIJRKKXMNW-UHFFFAOYSA-N 0.000 description 1
• 125000005518 carboxamido group Chemical group 0.000 description 1
• KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 1
• 229960005123 cariprazine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003874 central nervous system depressant Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960004782 chlordiazepoxide Drugs 0.000 description 1
• ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001761 chlorpropamide Drugs 0.000 description 1
• 230000001906 cholesterol absorption Effects 0.000 description 1
• 239000000064 cholinergic agonist Substances 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 229960001403 clobazam Drugs 0.000 description 1
• CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
• 229960004606 clomipramine Drugs 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• 229960002896 clonidine Drugs 0.000 description 1
• 229910000001 cobalt(II) carbonate Inorganic materials 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 238000009225 cognitive behavioral therapy Methods 0.000 description 1
• 239000002475 cognitive enhancer Substances 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 239000010779 crude oil Substances 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 239000003954 decarboxylase inhibitor Substances 0.000 description 1
• 208000018180 degenerative disc disease Diseases 0.000 description 1
• 229960001623 desvenlafaxine Drugs 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960001985 dextromethorphan Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 125000004663 dialkyl amino group Chemical group 0.000 description 1
• 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
• 229960004875 difluprednate Drugs 0.000 description 1
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000003372 dissociative anesthetic agent Substances 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
• 229960001253 domperidone Drugs 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229960005426 doxepin Drugs 0.000 description 1
• ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 201000002545 drug psychosis Diseases 0.000 description 1
• 229960002866 duloxetine Drugs 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
• 235000005686 eating Nutrition 0.000 description 1
• 238000002635 electroconvulsive therapy Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 230000006397 emotional response Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 229960004341 escitalopram Drugs 0.000 description 1
• WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
• GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 1
• 229960001578 eszopiclone Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 229960001519 exenatide Drugs 0.000 description 1
• PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 1
• 229960004979 fampridine Drugs 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 229960003472 felbamate Drugs 0.000 description 1
• WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
• 229960002724 fenoldopam Drugs 0.000 description 1
• TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
• 229960004009 fenoldopam mesylate Drugs 0.000 description 1
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000012025 fluorinating agent Substances 0.000 description 1
• 229960002419 flupentixol Drugs 0.000 description 1
• 229960002690 fluphenazine Drugs 0.000 description 1
• 229960004038 fluvoxamine Drugs 0.000 description 1
• CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• 229960003980 galantamine Drugs 0.000 description 1
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
• 239000003540 gamma secretase inhibitor Substances 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 229960000647 gepirone Drugs 0.000 description 1
• QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
• 210000002816 gill Anatomy 0.000 description 1
• 229960004580 glibenclamide Drugs 0.000 description 1
• 229960000346 gliclazide Drugs 0.000 description 1
• 229960004346 glimepiride Drugs 0.000 description 1
• WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
• 229960001381 glipizide Drugs 0.000 description 1
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229960002048 guanfacine Drugs 0.000 description 1
• 239000000380 hallucinogen Substances 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
• 229960001410 hydromorphone Drugs 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 230000002296 hyperlocomotor Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 239000003326 hypnotic agent Substances 0.000 description 1
• 230000001505 hypomanic effect Effects 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 229960004801 imipramine Drugs 0.000 description 1
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
• 239000000859 incretin Substances 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000035992 intercellular communication Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 229950003599 ipsapirone Drugs 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 229960002672 isocarboxazid Drugs 0.000 description 1
• HWXIVVHIYFTBBZ-UHFFFAOYSA-N isochromene Chemical compound C1=CC=C2[CH]OC=CC2=C1 HWXIVVHIYFTBBZ-UHFFFAOYSA-N 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
• 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 description 1
• 229960002623 lacosamide Drugs 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229960004002 levetiracetam Drugs 0.000 description 1
• HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
• 229960004502 levodopa Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229960002397 linagliptin Drugs 0.000 description 1
• 229960002701 liraglutide Drugs 0.000 description 1
• VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 description 1
• 229960001451 lisdexamfetamine Drugs 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 229960004391 lorazepam Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229950003467 lumateperone Drugs 0.000 description 1
• 230000029849 luteinization Effects 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 229960004090 maprotiline Drugs 0.000 description 1
• QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 229950004994 meglitinide Drugs 0.000 description 1
• BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
• 229960004640 memantine Drugs 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 238000003328 mesylation reaction Methods 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• 229960001252 methamphetamine Drugs 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229940042053 methotrimeprazine Drugs 0.000 description 1
• VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
• GWRXINICUFSGFD-UHFFFAOYSA-N methyl 2-(7-bromo-2,3-dihydro-1-benzofuran-5-yl)acetate Chemical compound BrC1=CC(=CC=2CCOC=21)CC(=O)OC GWRXINICUFSGFD-UHFFFAOYSA-N 0.000 description 1
• SURZCVYFPAXNGN-UHFFFAOYSA-N methyl-carbamic acid ethyl ester Chemical compound CCOC(=O)NC SURZCVYFPAXNGN-UHFFFAOYSA-N 0.000 description 1
• 229960001344 methylphenidate Drugs 0.000 description 1
• 108091070501 miRNA Proteins 0.000 description 1
• 239000002679 microRNA Substances 0.000 description 1
• 229960001110 miglitol Drugs 0.000 description 1
• 206010052787 migraine without aura Diseases 0.000 description 1
• RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
• 229960001785 mirtazapine Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
• 229960001165 modafinil Drugs 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• XNKCCCKFOQNXKV-ZRSCBOBOSA-N naloxegol Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC[C@@H]3OCCOCCOCCOCCOCCOCCOCCOC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 XNKCCCKFOQNXKV-ZRSCBOBOSA-N 0.000 description 1
• 229960005171 naloxegol Drugs 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 229960000698 nateglinide Drugs 0.000 description 1
• OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• JCSREICEMHWFAY-HUUCEWRRSA-N naxagolide Chemical compound C1=C(O)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 JCSREICEMHWFAY-HUUCEWRRSA-N 0.000 description 1
• 229950005651 naxagolide Drugs 0.000 description 1
• NNEACMQMRLNNIL-CTHHTMFSSA-N naxagolide hydrochloride Chemical compound Cl.C1=C(O)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 NNEACMQMRLNNIL-CTHHTMFSSA-N 0.000 description 1
• VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
• 229960001800 nefazodone Drugs 0.000 description 1
• 230000007383 nerve stimulation Effects 0.000 description 1
• 208000007431 neuroacanthocytosis Diseases 0.000 description 1
• 201000007599 neurodegeneration with brain iron accumulation 2a Diseases 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
• 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 239000003900 neurotrophic factor Substances 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 208000005346 nocturnal enuresis Diseases 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 239000002664 nootropic agent Substances 0.000 description 1
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
• UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
• 229960001158 nortriptyline Drugs 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229960004535 oxazepam Drugs 0.000 description 1
• ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 229960001816 oxcarbazepine Drugs 0.000 description 1
• CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 229960002085 oxycodone Drugs 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 229940124641 pain reliever Drugs 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• 208000021090 palsy Diseases 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 210000001152 parietal lobe Anatomy 0.000 description 1
• 229960002296 paroxetine Drugs 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229960005198 perampanel Drugs 0.000 description 1
• PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
• 229960001511 pergolide mesylate Drugs 0.000 description 1
• 229960000769 periciazine Drugs 0.000 description 1
• LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 229960000964 phenelzine Drugs 0.000 description 1
• ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
• 229960003243 phenformin Drugs 0.000 description 1
• YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
• 229960003634 pimozide Drugs 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
• 229960004310 piribedil Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• 125000005592 polycycloalkyl group Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 230000036515 potency Effects 0.000 description 1
• 229960003611 pramlintide Drugs 0.000 description 1
• 108010029667 pramlintide Proteins 0.000 description 1
• NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
• 229960004856 prazepam Drugs 0.000 description 1
• 229960001233 pregabalin Drugs 0.000 description 1
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
• 229960003111 prochlorperazine Drugs 0.000 description 1
• DWEQWXSKOHHBNT-SAPNQHFASA-N progabide Chemical compound C=1C=C(Cl)C=CC=1C(/NCCCC(=O)N)=C1/C=C(F)C=CC1=O DWEQWXSKOHHBNT-SAPNQHFASA-N 0.000 description 1
• 229960002752 progabide Drugs 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960002601 protriptyline Drugs 0.000 description 1
• BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
• 201000002274 psychologic vaginismus Diseases 0.000 description 1
• 238000001671 psychotherapy Methods 0.000 description 1
• 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 229960001150 ramelteon Drugs 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
• 229960000245 rasagiline Drugs 0.000 description 1
• 229960003770 reboxetine Drugs 0.000 description 1
• CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 229960002354 repaglinide Drugs 0.000 description 1
• 238000009256 replacement therapy Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000000979 retarding effect Effects 0.000 description 1
• 229960003312 retigabine Drugs 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229960004181 riluzole Drugs 0.000 description 1
• 238000006798 ring closing metathesis reaction Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229960004136 rivastigmine Drugs 0.000 description 1
• 239000011435 rock Substances 0.000 description 1
• 229960001879 ropinirole Drugs 0.000 description 1
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 description 1
• 229960003014 rufinamide Drugs 0.000 description 1
• NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 1
• 229950002652 safinamide Drugs 0.000 description 1
• 229960002052 salbutamol Drugs 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
• 229960004937 saxagliptin Drugs 0.000 description 1
• 108010033693 saxagliptin Proteins 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 230000004799 sedative–hypnotic effect Effects 0.000 description 1
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
• 229960002073 sertraline Drugs 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960004034 sitagliptin Drugs 0.000 description 1
• MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
• 229960001922 sodium perborate Drugs 0.000 description 1
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
• YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
• 201000002849 spasmodic dystonia Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 1
• 229960005126 tapentadol Drugs 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229950007151 taspoglutide Drugs 0.000 description 1
• 108010048573 taspoglutide Proteins 0.000 description 1
• WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
• 229960003188 temazepam Drugs 0.000 description 1
• HUHJUGPKFLYSDX-UHFFFAOYSA-N tert-butyl N-[(8-cyano-3,4-dihydro-1H-isochromen-1-yl)methyl]-N-methylcarbamate Chemical compound C(#N)C=1C=CC=C2CCOC(C=12)CN(C(OC(C)(C)C)=O)C HUHJUGPKFLYSDX-UHFFFAOYSA-N 0.000 description 1
• NKVNYOKPSZWUFY-UHFFFAOYSA-N tert-butyl N-[(8-fluoro-3,4-dihydro-1H-isochromen-1-yl)methyl]-N-methylcarbamate Chemical compound C1OC(C2=C(C1)C=CC=C2F)CN(C(=O)OC(C)(C)C)C NKVNYOKPSZWUFY-UHFFFAOYSA-N 0.000 description 1
• JSWCMZKDIONHTK-UHFFFAOYSA-N tert-butyl N-[2-[2-(1,1-difluoro-2-hydroxyethyl)phenyl]-2-hydroxyethyl]-N-methylcarbamate Chemical compound FC(CO)(F)C1=C(C=CC=C1)C(CN(C(OC(C)(C)C)=O)C)O JSWCMZKDIONHTK-UHFFFAOYSA-N 0.000 description 1
• MLCGUJAUQXYKSH-UHFFFAOYSA-N tert-butyl N-[2-[2-(1-chloro-2-hydroxyethyl)-6-fluorophenyl]-2-hydroxyethyl]-N-methylcarbamate Chemical compound ClC(CO)C1=C(C(=CC=C1)F)C(CN(C(OC(C)(C)C)=O)C)O MLCGUJAUQXYKSH-UHFFFAOYSA-N 0.000 description 1
• ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 1
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 229960005333 tetrabenazine Drugs 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000003396 thiol group Chemical class [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 229960002784 thioridazine Drugs 0.000 description 1
• 229960005138 tianeptine Drugs 0.000 description 1
• 229960005013 tiotixene Drugs 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 229960002277 tolazamide Drugs 0.000 description 1
• OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
• 229960005371 tolbutamide Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 229960004394 topiramate Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 229960004380 tramadol Drugs 0.000 description 1
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 238000011491 transcranial magnetic stimulation Methods 0.000 description 1
• 230000017105 transposition Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229960003386 triazolam Drugs 0.000 description 1
• JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
• ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
• 229960002324 trifluoperazine Drugs 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 229960001032 trihexyphenidyl Drugs 0.000 description 1
• LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
• 229960002431 trimipramine Drugs 0.000 description 1
• ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 208000032521 type II spinal muscular atrophy Diseases 0.000 description 1
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
• 210000001186 vagus nerve Anatomy 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 229940102566 valproate Drugs 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229960004688 venlafaxine Drugs 0.000 description 1
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
• PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
• RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical compound Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 description 1
• 229960003381 vilazodone hydrochloride Drugs 0.000 description 1
• SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
• 229960001254 vildagliptin Drugs 0.000 description 1
• 229960001255 viloxazine Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 229960002263 vortioxetine Drugs 0.000 description 1
• YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 description 1
• 230000002618 waking effect Effects 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229960000607 ziprasidone Drugs 0.000 description 1
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
• ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
• 229960001475 zolpidem Drugs 0.000 description 1
• 229960002911 zonisamide Drugs 0.000 description 1
• UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
• 229960000820 zopiclone Drugs 0.000 description 1
• WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
• 229960004141 zuclopenthixol Drugs 0.000 description 1